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B7-DC, one of the recently described B7 family members, has the capacity to inhibit T cell 
responses via engagement of the immunoreceptor tyrosine-based inhibitory motif–containing 
inhibitory PD-1 receptor as well as enhance responses via an as yet unidentified costimulatory 
receptor. B7-DC is highly homologous to a coinhibitory B7 family member, B7-H1, which also 
binds PD-1. It is currently unclear which B7-DC function—costimulation or inhibition—
predominates in vivo. To study in vivo functions of B7-DC, we evaluated immune responses in 
B7-DC knockout (KO) mice. Although not eliminated, interferon-
 
 
 
 (IFN-
 
 
 
) production by CD4 
T cells and IFN-
 
 
 
–dependent humoral responses were reduced in B7-DC KO mice relative to 
wild type mice. Antigen-specific CD8 T cell responses and cytotoxic T lymphocyte (CTL) 
activity were also diminished in B7-DC KO mice. Hepatic tumors grew more quickly in B7-DC 
KO mice, associated with a decrease in intrahepatic tumor-specific CD8 T cells. These results 
highlight the contrasting in vivo roles of B7-DC and B7-H1 and indicate that B7-DC 
functions as a tuning molecule, selectively augmenting T helper 1 and CTL responses.
 
The B7 family of costimulatory and coinhibi-
tory molecules critically regulates qualitative
and quantitative aspects of T cell responses to
antigen (1, 2). The complexity of this regula-
tion depends upon a number of factors including
differential kinetics and patterns of expression of
the B7 family molecules by different APC
types; differential kinetics, patterns of expression;
and signaling outcomes of their multiple recep-
tors on T cells; and effects of backward signaling
by the B7 family members themselves. The
well-characterized prototype B7 family mole-
cules B7-1 (CD80) and B7-2 (CD86) costim-
ulate T cells via interaction with CD28 ex-
pressed on both naive and activated T cells and
down-regulate T cell responses via interaction
with the activation-dependent counter-regula-
tory receptor CTLA-4 (3, 4). Although B7-1 and
B7-2 are considered largely redundant, recent
evidence suggests partially distinct roles resulting
from different capacities for homodimerization
and resultant binding kinetics in CD28 and
CTLA-4.
B7-H1 (PDL1) and B7-DC (PDL2) repre-
sent a second molecular pair within the B7
family (5–8). They are the most homologous of
any pair of B7 family molecules, and both bind
PD-1, an immunoreceptor tyrosine-based in-
hibitory motif–containing receptor expressed
on activated T cells (and B cells) that seems to
down-modulate T cell responses via multiple
mechanisms including cell-cycle inhibition and
apoptosis induction (9). In accordance with
their PD-1 specificity, both B7-H1 and B7-DC
were shown to inhibit T cell responses under
certain conditions of in vitro T cell stimulation
(5, 10–12). Paradoxically, both molecules also
were shown to costimulate T cells in vitro under
some conditions (6, 7, 13, 14). A partial expla-
nation for these apparently conflicting results
came from two lines of investigation that pro-
vided evidence that T cell costimulation by
B7-H1 and B7-DC occurs via a second recep-
tor. First, a structure-based mutational analysis
of B7-H1 and B7-DC revealed PD-1 binding
residues that, when mutated, result in mole-
cules that have lost PD-1 binding capacity but
retained costimulatory activity (13). Another set
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of studies demonstrated that naive T cells from PD-1 KO
mice are costimulated by B7-DC in a similar fashion to naive
T cells from WT mice (13, 14). B7-H1 can also stimulate
PD-1 KO T cells (Housseau F, unpublished data). Taken to-
gether, these results suggest a model similar to the B7-1/2 pair
in which naive T cells express a costimulatory receptor, and
activated T cells turn on an inhibitory receptor.
Despite these analogies with the B7-1/2 pair, the radi-
cally different expression patterns of B7-H1 and B7-DC sug-
gest that they could have distinct in vivo biologic functions.
B7-H1 is quite ubiquitously expressed on the surface of
many cell types, including stromal cells within many organs.
In contrast, although B7-DC mRNA has been reported in
many tissue types, surface expression is much more re-
stricted, in particular to DCs and a subset of macrophages
(5–7, 15, 16). Many tumors express B7-H1, but relatively
few express B7-DC. The in vivo role of B7-H1 has been
studied much more extensively than that of B7-DC. B7-H1
expression on tumors inhibits the activity of tumor-specific
CTLs (17). Apoptosis of CD8 T cells in the liver is dramati-
cally reduced in B7-H1 KO mice, and hepatitis is increased
(18). These results point to an important inhibitory role for
B7-H1 in vivo, protecting both tissues and tumors from im-
mune attack. Collectively, these results support a predomi-
nantly negative regulatory role for B7-H1.
At present, analysis of the in vivo role of B7-DC has been
limited. The effects of in vivo anti-B7-DC mAb injection
have been variable in different model systems. In a model of
Th2-dependent asthma, anti-B7-DC antibodies exacerbated
disease in association with increased IL-4 production in the
lung (19). In an experimental autoimmune encephalitis
model, anti-B7-DC antibody administration was reported to
diminish disease, whereas this treatment exacerbated autoim-
mune diabetes in nonobese diabetic (NOD) mice (20, 21).
Interpretation of these results is complicated by partial and
variable antagonistic activity of different antibodies, variable
tissue access, variable effects in inducing elimination of B7-
DC–expressing cells, and potential effects of backward signal-
ing into DCs through cross-linking of B7-DCs (22, 23). To
evaluate the in vivo role of B7-DC more definitively, we
have analyzed immune responses in B7-DC KO mice. Our
results demonstrate diminished but not absent Th1 and CTL
responses in B7-DC KO mice, indicating that, in contrast to
B7-H1, B7-DC serves as a costimulator of Th1 responses in
vivo and augments CTL responses. Further, B7-DC seems to
serve more as a rheostat rather than as an on–off switch for
these immune functions.
 
RESULTS
Leukocyte populations are normal in B7-DC knockout mice
 
To knock out the B7-DC gene and simultaneously introduce
a reporter for B7-DC expression, we used a knock-out/
knock-in construct that replaced B7-DC with the 
 
EGFP
 
gene (Fig. 1a). Animals derived from recombinant embryonic
Figure 1. Generation and characterization of B7-DC gene KO mice. 
(a) The targeting map of B7-DC genomic locus. The signal peptide with the 
ATG initiation codon of B7-DC was replaced with EGFP and NEO cassette. 
After mating with CMV-Cre mouse, the NEO cassette was deleted. The 5  
probe indicated was used for Southern blot analysis of mouse genomic 
DNA. (b) Flow cytometry analysis of B7-DC, B7-H1, B7-1, B7-2, and MHC 
class II (H-2Kd) expression on the surface of BMDCs from WT and B7-DC 
KO mice on the BALB/c background. Mouse BM cells were cultured with 
GM-CSF for 6 d and with GM-CSF and IL-4 for additional 2 d. Data are 
representative of six experiments. (c) Absolute numbers of BMDCs from 
WT or B7-DC KO mice (n   13/group). 
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stem cells were backcrossed nine generations onto the
BALB/c background. Initially, myeloid and lymphoid popu-
lations from the thymus, secondary lymphoid tissues, and
liver were analyzed. Overall cell numbers and proportions of
standard subsets of T, B, NK, NK T cells, and DC were fairly
similar in the thymus and spleen of WT and B7-DC KO
mice (Fig. S1 available at http://www.jem.org/cgi/content/
full/jem.20050072/DC1). This similarity contrasts with the
recently reported B7-H1 KO mice, in which the total num-
ber of CD8 T cells in the liver is significantly increased (18).
Importantly, the expression pattern of MHC class II as well as
other B7 family members, including B7-1 (CD80), B7-2
(CD86), and B7-H1, on DCs was not appreciably affected by
the absence of B7-DC (Fig. 1b). Likewise, the cell yield from
bone marrow–derived DC (BMDC) cultures was essentially
identical in WT and B7-DC KO mice (Fig. 1c).
 
In vitro T cell responses in the absence of B7-DC
 
As described in earlier publications, surface expression of B7-
DC is largely restricted to DCs and a subset of macrophages,
with essentially no detectable expression on B cells or T cells
in any activation state (16). Indeed, purified T cells from B7-
DC KO mice proliferate in response to the T cell mitogen,
Concanavalin A (ConA), equivalently to WT T cells (Fig.
2a). In contrast, naive OVA-specific CD4 T cells (from the
DO.11.10 TCR transgenic line) are stimulated to proliferate
somewhat less efficiently than WT DCs in vitro by OVA-
pulsed B7-DC KO DCs (Fig. 2b). Given that MHC II, B7-1,
B7-2, and B7-H1 are not altered on B7-DC KO DCs (Fig.
1b), these data are compatible with a costimulatory role for
B7-DC. However, they could also reflect effects on other
costimulatory molecules or backward signaling into DCs by
B7-DC.
Figure 2. In vitro T cell proliferation. (a) Purified T cells from WT and 
B7-DC KO mice were cultured with the indicated concentration of ConA 
for 3 d. 16 h before the end of culture, 3H-thymidine was added, and its 
uptake was measured. (b) Purified DO11.10 CD4 T cells were labeled with 
CFSE and cultured for 3 d with BMDCs from WT and B7-DC KO mice in the 
presence of various concentrations of OVA323-339 peptide. CFSE dilution as 
a measure of cell division of CD4 KJ1-26  T cells was analyzed by FACS. 
Data are representative of three independent experiments. 
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Earlier studies have shown that when plate-bound B7-
DC-Fc plays a costimulatory role, particularly when used in
conjunction with B7-1-Fc or B7-2-Fc, there is a pro-
nounced effect on IL-2 and IFN-
 
 
 
, (14). We therefore fur-
ther evaluated the role of B7-DC in Th1 versus Th2 differ-
entiation upon culturing purified DO11.10 CD4 T cells
with BMDCs from WT or B7-DC KO mice under Th1- or
Th2-generating conditions in the presence of OVA
 
323-339
 
peptide. Fig. 3 shows that T cells cultured with BMDCs
from B7-DC KO mice generated roughly 40% fewer
IFN-
 
 
 
 
 
 cells than did T cells cultured with BMDCs from
WT mice (59.7% vs. 35.0%, respectively). The same reduc-
tion in IFN-
 
 
 
 
 
 CD4 T cells was observed in the presence of
additional anti-mouse CD3 antibody during restimulation
(81.7% vs. 50.6%, respectively). In contrast, culture under
Th2-generating conditions failed to demonstrate a significant
difference in IL-4
 
 
 
 
 
T cells whether WT or B7-DC KO
BMDCs were used.
These results support the notion that B7-DC selectively
costimulates Th1 responses. The effect is certainly not all-or-
none, suggesting the this particular B7 family member tunes
IFN-
 
 
 
 responses rather than being absolutely necessary for
their generation.
 
Effect of B7-DC on in vivo antigen-specific T cell 
proliferative and cytokine responses
 
To analyze the role of B7-DC in the priming of in vivo im-
mune responses, we adoptively transferred naive OVA-spe-
cific DO11.10 cells and measured responses to immunization
with peptide loaded onto DCs. 5 million purified carboxy-
fluorescein succinimidyl (CFSE)-labeled DO11.10 CD4 T
cells were transferred into WT or B7-DC KO mice on d
 
 
 
1. Because it remains unresolved whether priming by ex
vivo–loaded DCs involves direct presentation or transfer of
antigen from injected DCs to endogenous DCs, the geno-
type of the BMDCs was matched to the immunized host;
that is, WT mice were immunized with WT DCs, and B7-
DC KO mice were immunized with B7-DC KO BMDCs.
This design assures that all potential DCs presenting antigen
in vivo are uniformly WT or B7-DC KO. When these mice
were immunized by OVA
 
323-339
 
 peptide–pulsed BMDCs, a
significant effect of B7-DC on T cell expansion was ob-
served. Whereas OVA-specific KJ1-26
 
 
 
 T cells expanded to
11.6%, 1.8%, 4.1%, and 7.6% of total CD4 T cells in spleen,
peripheral lymph nodes (PLN), liver, and hepatic lymph
node (HLN), respectively, expansion in B7-DC KO mice
was 7.7% (34% reduction), 0.9% (50% reduction), 2.4%
Figure 3. In vitro Th1 and Th2 cell generation by dendritic cells.
1   104 purified DO11.10 CD4 T cells were cultured with 3  104 BMDCs 
from WT or B7-DC KO mice with OVA323-339 peptide for 5 d in the presence 
of recombinant IL-12 and anti-IL-4 mAb for Th1 generation or recombi-
nant IL-4 and anti-IFN-  mAb for Th2 generation. 6 h before end of cul-
ture, additional OVA323-339 peptide with or without anti-CD3 mAb was 
added for restimulation. After surface CD4 was stained, cells were fixed 
and permeabilized, and intracellular IFN-  and IL-4 were stained. The data 
shown are gated on CD4  cells. Data are representative of four indepen-
dent experiments. 
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(42% reduction), and 3.0% (61% reduction) in the respective
compartments by d 3 after immunization (Fig. 4a). By d 5,
B7-DC KO mice showed similar reductions relative to those
in WT mice in all compartments except PLN, in which
there was no significant reduction (Fig. 4b). A more pro-
nounced effect of B7-DC deletion was observed in the anal-
ysis of CFSE dilution in DO11.10 CD4 T cells (Figs. 4, c
and d, and Fig. S2, available at http://www.jem.org/cgi/
content/full/jem.20050072/DC1). For example, the ratios
of undivided cells (no CFSE dilution) to undivided cells
were significantly different, particularly in the liver and
HLN, on d 3 and d 5. On d 3, there were 8.7 times more
undivided cells in B7-DC KO mouse liver than in WT
mouse liver and 2.7 times more undivided cells in B7-DC
KO mouse HLN than in WT mouse HLN. On d 5 there
were 2.9 times more undivided cells in B7-DC KO mouse
liver than in WT mouse liver and 2.4 times more undivided
cells in B7-DC KO mouse HLN than in WT mouse HLN).
Analysis of CD4
 
 
 
 KJ1-26
 
 
 
 T cell expansion and CFSE dilu-
tion showed similar trends in differences between B7-DC
KO and WT mice among the various compartments; namely,
liver 
 
 
 
 HLN 
 
 
 
 spleen 
 
 
 
 PLN.
To follow up on the in vitro results suggesting that B7-
DC selectively contributes to Th1 responses, we analyzed in
vivo cytokine responses to immunization with OVA pep-
tide-pulsed DCs in animals receiving DO11.10 CD4 T cells
1 d before immunization, as described previously. To avoid
effects on cytokine patterns caused by in vitro stimulation,
we analyzed cytokine mRNA by quantitative RT-PCR
from OVA-specific T cells purified directly from immunized
animals. 5 d after immunization, CD4
 
 
 
KJ1-26
 
 
 
 T cells were
sorted out, and the RNA was prepared for quantitative RT-
PCR. Cytokine responses as assessed by mRNA were highly
antigen specific—virtually none were detected in purified
CD4
 
 
 
KJ1-26
 
 
 
 T cells after immunization with unpulsed
DCs. Significantly less IFN-
 
 
 
, slightly less IL-2, and signifi-
cantly more IL-4 was consistently observed in B7-DC KO
mice immunized with peptide-pulsed B7-DC KO BMDCs
Figure 4. In vivo CD4 T cell stimulation after DC immunization. 
5  106 purified CFSE-labeled DO11.10 CD4 T cells were transferred into 
WT or B7-DC KO mice on d  1. Mice were then immunized with 1  106 
OVA323-339 peptide–pulsed BMDCs on d 0. Peptide-pulsed BMDCs from WT 
mice were injected into WT mice, and peptide-pulsed BMDCs from B7-DC KO 
mice were injected into B7-DC KO mice, respectively. (a and b) Propor-
tion and (c and d) cell division (CFSE dilution) of CD4 KJ1-26  T cells in 
spleen, PLN, liver, and HLN were analyzed by FACS on d 3 (a and c) and d 
5 (b and d). The CFSE-labeled CD4 KJ1-26  T cells in liver, immunized 
with BMDCs without OVA323-339 peptide, are also shown in Fig. S2 as neg-
ative controls. (e) The absolute number of DO11.10 CD4 T cells in spleen 
and liver was calculated on d 3 and 5 by the formula: total cell number   
percent CD4  cells   percent CD4  cells staining with KJ1-26. *, Signifi-
cant difference (P   0.001) observed in liver of six pairs of B7-DC KO 
mice and WT mice on d 3 and 5. Data are representative of three inde-
pendent experiments.
Figure 4 (continues on next page) 
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than in WT mice immunized with WT BMDCs (Fig. 5).
These results demonstrate that, in the absence of B7-DC,
cytokine production is skewed from Th1 to Th2 with de-
creased IFN-
 
 
 
 and increased IL-4 production. As in the in
vitro studies, the effect is partial, compatible with a tuning
function for B7-DC.
 
Effect of B7-DC on antibody-class switching
 
The patterns of cytokine expression from both the in vitro
and in vivo studies described previously suggested that B7-
DC has a positive costimulatory role in enhancing Th1-type
responses. It was therefore of interest to analyze the effect of
B7-DC deletion on antibody isotypes in response to immu-
nization, because isotype switching is dependent on produc-
tion of specific cytokines by Th cells and, as such, partially
reflects Th1/2 balance. WT and B7-DC KO mice were im-
munized with the T cell–dependent antigen NP
 
17
 
-KLH in
alum, and the serum levels of NP-specific antibody isotypes
were measured. Significantly, all classes of antibody were es-
sentially identical in WT and B7-DC KO mice with the ex-
ception of the IFN-
 
 
 
–dependent IgG2a class, which was
dramatically reduced in B7-DC KO mice (Fig. 6). These re-
sults support a functional role for B7-DC in costimulating
IFN-
 
 
 
–dependent class switching in vivo.
 
Effect of B7-DC on in vivo cytotoxic T lymphocyte priming
 
To determine whether B7-DC plays a role in MHC class I–
restricted CTL generation, we transferred 2 
 
 
 
 10
 
6
 
 T cells
from H-2Kd
 
 
 
 hemagglutinin (HA)-specific TCR transgenic
mice (24, 25) into BALB/c WT or B7-DC KO mice and
immunized them with unloaded BMDCs as control or with
BMDCs loaded with the cognate peptide (HA
 
518-526
 
). As in 
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the in vivo CD4 T cell experiments, WT mice were immu-
nized with WT BMDCs, and B7-DC KO mice were im-
munized with B7-DC KO BMDCs. As with antigen-spe-
cific CD4 T cells, expansion of HA-specific CD8 T cells was
lower in B7-DC KO mice than in WT mice, particularly in
the liver and, to a lesser extent, in the spleen (Fig. 7). As
with CD4 T cells, the smallest difference in absolute num-
bers of HA-specific CD8 T cells in WT and B7-DC KO
mice was observed in PLN. To measure CTL activity di-
rectly, an in vivo CTL assay was done in which two popula-
tions of BALB/c splenocytes differentially labeled with
CFSE, one of which loaded with HA
 
518-526
 
, were transferred
into the immunized mice. As a control, some immunized
mice received splenocytes in which neither the CFSE
 
high
 
 or
CFSE
 
low
 
 cells were peptide loaded. In vivo CTL activity is
determined based on the selective reduction in ratio of pep-
tide-loaded cells (CFSE
 
low
 
) to unloaded cells (CFSE
 
high
 
) re-
isolated from the spleen 10 h after injection. As seen in Fig.
7b, in vivo CTL activity in immunized B7-DC KO mice
was roughly half that of WT mice. Thus, B7-DC seems to
play a costimulatory role in vivo for CTL proliferation and
activation, either indirectly by enhancing Th function or di-
rectly by costimulating CD8 T cells. Because only the CTL
epitope of HA was used in the immunizations, a direct role
in CD8 T cell costimulation independent of CD4 T cells is
the most likely mechanism. This notion is supported by
findings that B7-DC can strongly costimulate purified CD8
T cells in vitro (15).
 
Effect of B7-DC on tumor growth and tumor-specific CD8 
T cell responses
 
IFN-
 
 
 
 responses are crucial for both natural and induced an-
titumor immunity. Tumors arise more frequently and grow
more quickly in mice with deletions in either the 
 
IFN-
 
 
 
gene or components of the IFN-
 
 
 
 signaling pathway. In
general, strong Th1 responses tend to be linked to strong
CD8 CTL responses, and the combination of strong Th1
and strong CD8 CTL responses is typically associated with
successful antitumor immunity. We therefore analyzed the
growth of hepatic metastases of the well-characterized CT26
colon tumor in WT and B7-DC KO mice as well as the
CD8 T cells specific for the immunodominant H-2L
 
d
 
-
restricted CT26 antigen, AH1. CT26 is a partially immuno-
genic tumor, because injection of WT tumor cells into
BALB/c mice elicits an AH1-specific T cell response. This
CD8 T cell response slows tumor growth, but the tumor ul-
timately outgrows the antitumor immune response and kills
the host animal. The mortality rate in CT26-bearing mice is
roughly proportional to the strength of the natural antitumor
response generated, because CD8-depleted animals succumb
to tumor faster than WT animals. Fig. 8a demonstrates that
Figure 5. In vivo Th1 response in B7-DC KO mice. 5  106 purified 
DO11.10 CD4 T cells were adoptively transferred into WT and B7-DC KO 
mice on d  1 as in Fig. 4. Mice were then immunized with 106 OVA323-339 
peptide-pulsed BMDCs on d 0. Peptide-pulsed BMDCs from WT mice were 
injected into WT mice, and peptide-pulsed BMDCs from B7-DC KO mice 
were injected into B7-DC KO mice, respectively. On d 5, CD4 KJ1-26  T 
cells were sorted out, and their mRNA was extracted. The expression level 
of each cytokine was detected by real-time RT-PCR, and relative tran-
scripts were calculated by the formula given in Material and methods. 
Data are representative of three independent experiments.
Figure 6. Class switching of antibodies in B7-DC KO mice. 100  g 
of NP17-KLH with alum was injected twice (2-wk interval between injec-
tions) into WT mice (n   7) or B7-DC KO mice (n   7). Sera were collected, 
and the titers of isotype of NP17-specific antibody were evaluated by 
ELISA. Each dot indicates the titer of a single mouse. *, Significantly differ-
ent (P   0.001) from WT mice.B7-DC COSTIMULATES Th1 AND CTL RESPONSES | Shin et al. 1538
B7-DC KO mice bearing hepatic metastases of CT26 die
more quickly than WT mice. This mortality is associated
with more rapid growth of CT26 tumors in the liver (Fig.
8b). Tetramer staining of AH1-specific CD8 T cells reveals a
marked decrease in the number of AH1-specific CD8 T cells
in the livers of tumor-bearing B7-DC KO mice relative to
WT mice (Fig. 8, c and d). Thus, B7-DC seems to contrib-
ute in a positive fashion to the endogenous generation of in-
trahepatic CT26-specific CD8 responses in animals bearing
hepatic CT26 metastases.
DISCUSSION
We present in vitro and in vivo experiments in B7-DC KO
mice that support a predominantly costimulatory role for B7-
DC in the generation of both Th1 and CTL responses. In
some cases, decreased IFN-  responses in B7-DC KO mice
are associated with increased IL-4 (Th2) responses (Fig. 5),
whereas in other cases, such as isotype switching, IL-4–depen-
dent antibody isotypes (IgG1) are unaffected. In all cases, the
effects are partial rather than complete. We therefore propose
that, unlike a molecule such as T-bet, on which Th1 re-
sponses depend absolutely (26), the role of B7-DC is to
amplify or tune Th1 responses. Fine-tuning of immune re-
sponses seems to be critical so that they do not undershoot or
overshoot. The importance of not undershooting the re-
sponse to an infectious organism is obvious. Conversely, the
toxicities of overzealous immune responses are readily appar-
ent in mice deficient in inhibitory checkpoint molecules and
in humans treated with antibodies such as anti-CTLA-4 (27).
The most straightforward interpretation of these results is
that decreased IFN-  and CTL responses in B7-DC KO mice
are caused by loss of a costimulatory signal to T cells that in-
teracts with B7-1/2 costimulation. However, an additional
possibility is that DC activation caused by backward signaling
by B7-DC is diminished. The fact that B7-1, B7-2, and sur-
face MHC II are not appreciably different in B7-DC KO
mice and WT mice suggests that DC activation status is not
appreciably affected by the absence of B7-DC. Nonetheless, a
definitive distinction between effects on forward versus back-
ward signaling will require further experimentation.
Taken together, our results strongly refute the notion
that B7-DC is a redundant inhibitory ligand for B7-H1,
even though both bind PD-1. In particular, the finding of
diminished CD4 and CD8 responses in the livers of B7-DC
KO mice stands in striking contrast to the increased numbers
and responses of activated CD8 T cells in the livers of B7-
H1 KO mice (18). Direct comparisons between these two
KO models in identical systems and strain backgrounds re-
main to be made. However, a preliminary picture of distinct
roles for these B7 family members seems to be emerging
from the different expression patterns seen in B7-DC (pre-
dominantly DCs) and B7-H1 (expression on both hemato-
poietic and nonhematopoietic cells of peripheral organs as
well as many tumors) mice and the respective KO mice.
Thus, B7-DC seems to have a primarily costimulatory role
in immune priming, whereas B7-H1 has a predominantly
down-modulating role for activated T cells in peripheral or-
gans and tumors. Further support for this distinct physiology
comes from the findings of Liu and colleagues that B7-DC–
transfected tumors enhance antitumor immunity in contrast
to B7-H1–expressing tumors that are protected from elimi-
nation by activated tumor-specific T cells (17, 28). The find-
ing that tumors grow faster and elicitation of tumor-specific
CD8 T cells is impaired in B7-DC KO mice further accen-
tuates the physiologic differences between these two mole-
cules and suggests that B7-DC signals may significantly en-
hance antitumor immunity.
Many questions remain to be answered about B7-DC
physiology. Foremost is the identification of its cognate co-
stimulatory receptor. We hypothesize that the costimulatory
role of B7-DC observed in vivo is largely mediated by this
Figure 7. CD8 T cell responses and CTL activity in B7-DC KO mice. 
2   106 T cells from H-2Kd  HA-specific TCR transgenic mice (clone 4 
mice) were transferred into BALB/c WT or B7-DC KO mice on d  1 followed 
by immunization with 1  106 peptide (HA518-526)-loaded BMDCs. As in the 
CD4 T cell experiments in Figs. 4 and 5, WT mice were immunized with WT 
BMDCs, and B7-DC KO mice were immunized with B7-DC KO BMDCs. 
(a) Expansion of HA-specific CD8 T cells was measured by FACS analysis of 
hepatic, lymph node, and splenic lymphocytes. Because there is no clono-
typic antibody for this TCR, donor clone 4 T cells were marked with Thy1.1, 
and recipients were Thy1.2. (b) To measure CTL activity directly, an in vivo 
CTL assay was done in which two populations of differentially CFSE-
labeled Balb/c splenocytes, one of which was loaded with HA518-526, were 
transferred into the immunized mice. As a control, some immunized mice 
received splenocytes in which neither the CFSEhi or CFSElo cells were 
peptide loaded. In vivo CTL activity is determined based on the selective 
reduction in the ratio of peptide-loaded cells (CFSElo) to unloaded cells 
(CFSEhi) reisolated from the spleen 10 h after injection, calculated as 
described in Materials and methods. Data are representative of three 
independent experiments.JEM VOL. 201, May 16, 2005 1539
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costimulatory receptor rather than by PD-1. Consistent with
this notion, treatment of mice with anti-PD1 antibodies did
not alter B7-DC costimulatory effects (unpublished data).
However, it is possible that, under certain circumstances,
PD-1 may transmit costimulatory rather than inhibitory sig-
nals. In addition, it will be important to determine how B7-
DC signals interact with other signaling pathways that affect
the Th1/Th2 balance. Along these lines, we are crossing the
B7-DC KO mice onto a C57/BL6 background, which is
more “Th1 prone” than the BALB/c background on which
the current studies were performed. A recent study sug-
gested that the IFN-  receptor differentially localizes into
the immune synapse in these two strains (29). Comparison
between these two strains may allow us to determine
whether the Th1 skewing by B7-DC is affected by interac-
tions with other background genes.
MATERIALS AND METHODS
Mice. 6–8-week-old BALB/c mice and antigen-specific TCR transgenic
DO11.10 mice (H-2d) were purchased from the National Cancer Institute
and Jackson ImmunoResearch Laboratories, respectively. Thy1.1 back-
ground HA (clone 4) transgenic mice were the gift from E. Fuchs (Johns
Hopkins University). B7-DC knock-out/knock-in mice were generated us-
ing standard methodologies (30). A genomic fragment containing exon 2 of
the B7-DC gene, which includes first methionine, was cloned from a 129/
SvJ mouse genomic library. The short and long fragments, two of loxP sites
and one of EGFP site (CLONTECH Laboratories, Inc.) were incorporated
into pNTKV1901 (Stratagene; Fig.1 a). This targeting vector was linearized
and electroporated into R1 embryonic stem cells. Genomic DNAs from 288
G418-resistant clones were digested with BamHI and screened by Southern
blot using 5  probe. Eight homologous recombinants were obtained. Germ-
line chimeras were generated from embryonic stem #144 by aggregation
with d-2.5 embryonic 8 cells. The NEO cassette was deleted by crossing
with Cre transgenic mice (Jackson ImmunoResearch Laboratories), and its
deletion was confirmed by Southern blot and PCR (unpublished data). Off-
Figure 8. Antitumor responses in B7-DC KO mice. Hepatic metastases 
of CT26 were established by intrahemisplenic injection of 1   105 CT26 
cells into either WT or B7-DC KO mice on d 0 (n   10). (a) Mouse survival 
was observed (P   0.01). (b) Livers were excised from WT and B7-DC KO 
mice on d 15, and liver weight and number of tumor nodules was mea-
sured. (c) Hepatic lymphocytes were isolated on d 3 and stained with AH-1 
peptide–loaded Ld tetramer or control ( -galactosidase–loaded Ld 
tetramer). (d) Total number of AH-1–specific CD8 T cells were analyzed by 
FACS staining. Data in b, c, and d are representative of three independent 
experiments.B7-DC COSTIMULATES Th1 AND CTL RESPONSES | Shin et al. 1540
spring were backcrossed with BALB/c more than nine generations and
typed as B7-DC WT and KO by Southern blot and PCR. B7-DC expres-
sion was completely abolished on BMDCs (Fig. 1), and spleen DCs (unpub-
lished data). All experimental protocols were reviewed and approved by
Johns Hopkins University Institutional Animal Care and Use Committee.
Antibodies and reagents. PE-conjugated anti-mouse B7-DC (TY25)
and anti-mouse B7-H1 (M1H6) mAbs were purchased from eBioscience.
PE-conjugated anti-mouse OVA-specific TCR (KJ1-26) mAb was pur-
chased from Caltag Laboratories. Purified anti-mouse CD16/32 (2.4G2),
IL-4 (BVD-1D11), and IFN-  (R4-6A2) mAbs, PE-conjugated CD8 (Ly-2),
CD80 (1G10), CD86 (GL1), Pan-NK cells (DX5), and I-Ad (AMS-
32.1)  mAbs, Cy-Chrome-conjugated CD45R/B220 (RA3-6B2) mAbs,
and APC-conjugated CD3 (145-2C11), CD4 (RM4-5), and CD11c (HL3)
mAbs were purchased from BD Biosciences. Recombinant mouse GM-
CSF, IL-4, and IL-12 were purchased from R&D Systems.
Cell preparations and in vitro cultures. For in vitro T cell assays, sin-
gle-cell suspensions of spleen from B7-DC WT or KO mice were prepared
by purification by Pan T cell isolation kit (Miltenyi Biotec) and cultured in
complete medium with ConA for 72 h. The last 18 h before end of culture,
3H-thymidine was pulsed, and its incorporation was measured. For antigen-
specific responses, CD4 T cells from DO11.10 mice were purified by using
a CD4  T cell isolation kit (Miltenyi Biotec) and labeled with CFSE before
culture. The purity of CD4 T cells was monitored by FACS and was always
 97%. BMDCs were prepared by culturing with recombinant mouse GM-
CSF (1,000 unit/ml) in the presence or absence of IL-4 (1,000 unit/ml).
Flow cytometric analysis. Cells were preincubated with unlabeled anti-
CD16/32 mAb to avoid nonspecific binding of antibodies to Fc receptor and
then incubated with PE- or APC-conjugated mAb. After washing twice
with FACS buffer, the stained cells (live-gated on the basis of forward and
side scatter profiles) were analyzed on a FACSCalibur (BD Biosciences).
Intracellular staining. 1.0   104 purified CD4 T cells from DO11.10
mice were cultured for 5 d with 3.0   104 BMDCs and 0.3  g/ml of
OVA323-339 peptide in the presence of recombinant IL-12 (1.0 unit/ml) and
anti-mouse IL-4 mAb (10  g/ml) for Th1 generation or with recombinant
IL-4 (100 unit/ml) and anti-mouse IFN-  mAb (10  g/ml) for Th2 gener-
ation. 6 h before the end of culture, additional OVA323-339 peptide (1.0  g/
ml) and GolgiStop (BD Biosciences) were added to each well for restimula-
tion with or without purified anti-CD3 mAb (1.0  g/ml). After surface
CD4 was stained, cells were fixed and permeabilized by Cytofix/Cytoperm
kit (BD Biosciences). Then intracellular IFN-  and IL-4 were stained and
analyzed by FACS.
In vivo proliferation assay. 5 million purified CD4 T cells from DO11.10
mice or CD8 T cells from clone 4 mice were labeled with CFSE and trans-
ferred to WT or B7-DC KO mice on d  1. For immunization, OVA323-339
peptide– or HA518-526 peptide– pulsed BMDCs were injected into WT or B7-
DC KO mouse on d 0. Peptides were obtained from Colorado State Univer-
sity. Single-cell suspensions were prepared from each organ of immunized
mice, cell numbers were counted, and CFSE dilution of CD4 KJ1-26  T cells
or CD8 Thy1.1  T cells were analyzed by FACS. In vivo cytotoxic assay was
performed by transferring CFSEhi (1  M)- and CFSElo (0.1  M)-labeled
Balb/c splenocytes. HA518-526 peptide was pulsed only on the CFSElo popula-
tion. The proportions of CFSEhi and CFSElo cells were measured by FACS on
d 5, and the cytotoxicity was calculated by the formula: % cytotoxicity   (%
CFSEhi   %CFSEhi control)   100 / (% CFSEhi   % CFSElo control).
T helper cell 1/2 response in vivo. 5 million purified DO11.10 CD4
T cells were transferred intravenously on d  1. Mice were immunized with
1 million OVA323-339 peptide–pulsed BMDCs on d 0. 0.5 million
CD4 KJ1-26  T cells from spleen were sorted by FACS-Vantage (Becton
Dickinson) at the Johns Hopkins Medical Institutions Oncology Center
Cell Sorting Facility. The purity among live cells was  99%. Total mRNA
from sorted cells was extracted, and first-strand cDNA was prepared by
You-Prime First-Strand Beads (Amersham Biosciences). Real-time PCR
reactions were performed in ABI PRISM 7700 Sequence Detection System
(Applied Biosystems) as described (31, 32). Data were treated according to
the manufacturer’s instructions in User Bulletin #2. Briefly, standard curves
were prepared by plotting the cycle threshold (Ct) by log ng input RNA.
The inverse logs were calculated and experimental values were divided by
18s internal controls. Relative transcripts were determined by the formula:
1/2(CTtarget - CTcontrol).
Antibody class switching. Mice were injected with 100  g NP17-KLH
(Biosearch Technologies, Inc.) with alum (Pierce Chemical Co.) on d 0 and
14. Mice sera were collected on d 28. The titers of isotype and subclass of
anti-NP–specific antibody were detected by ELISA using NP25-BSA (Bio-
search Technologies, Inc.) for antibody capture and SBA Clonotyping sys-
tem/HRP kit (Southern Biotechnology Associates, Inc.) for detection (33).
Liver metastatic model and tumor specific cytotoxic T lymphocyte
detection. For generating liver-specific tumor metastasis, 1   105 cells of
the Balb/c mouse–derived colon cancer cell line, CT26 were injected via
the hemispleen technique on day 0 (34). Survival was monitored every day,
and all dead mice were confirmed to possess liver metastases. To analyze an-
tigen-specific CTLs after generating liver metastases of CT26, liver lympho-
cytes were extracted by the Percoll technique and stained with AH-1 pep-
tide–pulsed MHC class I tetramer together with anti-mouse CD8 mAb.
Online supplemental material. Fig. S1 shows the flow cytometric anal-
ysis of lymphocyte subsets in thymus and spleen of B7-DC KO mice. Fig.
S2 shows in vivo CD4 T cell proliferation in the liver after dendritic cell
immunization. Online supplemental material is available at http://www.
jem.org/cgi/content/full/jem.20050072/DC1.
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